Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Incyte's Oncology Strategy: Putting Its Eggs In Many Mechanistic Baskets

Executive Summary

Commercial success with Jakafi allows parallel development of many new cancer drug mechanisms beyond the IDO1 inhibitor epacadostat, which is on a fast track.


Related Content

Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor
Broad-Based Incyte/Merus Collaboration Includes Up To 11 Bispecific Antibody Programs
Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss


Related Companies